Anaplastic Oligoastrocytoma – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Anaplastic Oligoastrocytoma – Pipeline Review, H2 2016’, provides an overview of the Anaplastic Oligoastrocytoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Anaplastic Oligoastrocytoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anaplastic Oligoastrocytoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Anaplastic Oligoastrocytoma

The report reviews pipeline therapeutics for Anaplastic Oligoastrocytoma by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Anaplastic Oligoastrocytoma therapeutics and enlists all their major and minor projects

The report assesses Anaplastic Oligoastrocytoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Anaplastic Oligoastrocytoma

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Anaplastic Oligoastrocytoma

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Anaplastic Oligoastrocytoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Axelar AB

Cavion LLC

Celldex Therapeutics Inc

Novartis AG

Pfizer Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Anaplastic Oligoastrocytoma Overview 6

Therapeutics Development 7

Pipeline Products for Anaplastic Oligoastrocytoma - Overview 7

Pipeline Products for Anaplastic Oligoastrocytoma - Comparative Analysis 8

Anaplastic Oligoastrocytoma - Therapeutics under Development by Companies 9

Anaplastic Oligoastrocytoma - Therapeutics under Investigation by Universities/Institutes 10

Anaplastic Oligoastrocytoma - Pipeline Products Glance 11

Clinical Stage Products 11

Anaplastic Oligoastrocytoma - Products under Development by Companies 12

Anaplastic Oligoastrocytoma - Products under Investigation by Universities/Institutes 13

Anaplastic Oligoastrocytoma - Companies Involved in Therapeutics Development 14

Axelar AB 14

Cavion LLC 15

Celldex Therapeutics Inc 16

Novartis AG 17

Pfizer Inc 18

Anaplastic Oligoastrocytoma - Therapeutics Assessment 19

Assessment by Monotherapy Products 19

Assessment by Combination Products 20

Assessment by Target 21

Assessment by Mechanism of Action 23

Assessment by Route of Administration 25

Assessment by Molecule Type 27

Drug Profiles 29

AXL-1717 - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

CDX-1401 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

Cellular Immunotherapy for Gliomas - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

flucytosine + TBio-01 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

irinotecan hydrochloride + TBio-02 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

mibefradil dihydrochloride - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

nilotinib - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

palbociclib - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

Anaplastic Oligoastrocytoma - Dormant Projects 55

Anaplastic Oligoastrocytoma - Discontinued Products 56

Appendix 57

Methodology 57

Coverage 57

Secondary Research 57

Primary Research 57

Expert Panel Validation 57

Contact Us 57

Disclaimer 58

List of Tables

List of Tables

Number of Products under Development for Anaplastic Oligoastrocytoma, H2 2016 7

Number of Products under Development for Anaplastic Oligoastrocytoma – Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Number of Products under Investigation by Universities/Institutes, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Products under Development by Companies, H2 2016 12

Products under Investigation by Universities/Institutes, H2 2016 13

Anaplastic Oligoastrocytoma – Pipeline by Axelar AB, H2 2016 14

Anaplastic Oligoastrocytoma – Pipeline by Cavion LLC, H2 2016 15

Anaplastic Oligoastrocytoma – Pipeline by Celldex Therapeutics Inc, H2 2016 16

Anaplastic Oligoastrocytoma – Pipeline by Novartis AG, H2 2016 17

Anaplastic Oligoastrocytoma – Pipeline by Pfizer Inc, H2 2016 18

Assessment by Monotherapy Products, H2 2016 19

Assessment by Combination Products, H2 2016 20

Number of Products by Stage and Target, H2 2016 22

Number of Products by Stage and Mechanism of Action, H2 2016 24

Number of Products by Stage and Route of Administration, H2 2016 26

Number of Products by Stage and Molecule Type, H2 2016 28

Anaplastic Oligoastrocytoma – Dormant Projects, H2 2016 55

Anaplastic Oligoastrocytoma – Discontinued Products, H2 2016 56

List of Figures

List of Figures

Number of Products under Development for Anaplastic Oligoastrocytoma, H2 2016 7

Number of Products under Development for Anaplastic Oligoastrocytoma – Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Clinical Stage Development, H2 2016 11

Assessment by Monotherapy Products, H2 2016 19

Assessment by Combination Products, H2 2016 20

Number of Products by Top 10 Targets, H2 2016 21

Number of Products by Stage and Top 10 Targets, H2 2016 21

Number of Products by Mechanism of Actions, H2 2016 23

Number of Products by Stage and Mechanism of Actions, H2 2016 23

Number of Products by Routes of Administration, H2 2016 25

Number of Products by Stage and Routes of Administration, H2 2016 25

Number of Products by Molecule Types, H2 2016 27

Number of Products by Stage and Molecule Types, H2 2016 27

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2960

Saved reports